Your browser is no longer supported. Please, upgrade your browser.
Settings
CALA Calithera Biosciences, Inc. daily Stock Chart
CALA [NASD]
Calithera Biosciences, Inc.
Index- P/E- EPS (ttm)-0.99 Insider Own6.20% Shs Outstand33.84M Perf Week9.04%
Market Cap346.86M Forward P/E- EPS next Y-1.07 Insider Trans-21.75% Shs Float33.36M Perf Month-35.53%
Income-26.40M PEG- EPS next Q-0.23 Inst Own92.60% Short Float8.73% Perf Quarter-32.79%
Sales18.70M P/S18.55 EPS this Y-7.80% Inst Trans0.64% Short Ratio4.73 Perf Half Y-38.07%
Book/sh4.46 P/B2.30 EPS next Y-39.00% ROA-15.10% Target Price18.25 Perf Year205.97%
Cash/sh4.89 P/C2.09 EPS next 5Y75.00% ROE-19.70% 52W Range2.90 - 20.05 Perf YTD215.38%
Dividend- P/FCF22.38 EPS past 5Y- ROI- 52W High-48.88% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low253.45% ATR1.18
Employees50 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)30.88 Volatility7.94% 9.77%
OptionableYes Debt/Eq0.00 EPS Q/Q60.90% Profit Margin- Rel Volume1.65 Prev Close10.13
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume615.57K Price10.25
Recom1.60 SMA20-28.75% SMA50-34.02% SMA200-26.84% Volume1,012,652 Change1.23%
Oct-05-17Initiated William Blair Outperform
Apr-03-17Resumed Leerink Partners Outperform
Mar-28-17Reiterated H.C. Wainwright Buy $10 → $14
Jan-24-17Upgrade Citigroup Sell → Neutral
Jan-05-17Initiated H.C. Wainwright Buy $9
Oct-25-16Initiated Citigroup Sell
Jul-24-15Initiated Citigroup Buy
Nov-16-17 03:27PM  Calithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer Data SmarterAnalyst
Nov-08-17 01:43PM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : November 8, 2017 Capital Cube
Nov-07-17 10:03AM  Is Calithera Biosciences Inc (CALA) Undervalued? Simply Wall St.
08:01AM  Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting GlobeNewswire
Nov-06-17 08:05AM  Calithera Biosciences, Q3 Analysis, Analysts Target and Clinical Trials Review ACCESSWIRE
Nov-02-17 07:49AM  Calithera reports 3Q loss Associated Press +11.87%
07:30AM  Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Oct-26-17 08:48AM  Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics Zacks
Oct-25-17 08:36AM  5 Stocks in Focus on New Analyst Coverage Zacks
Oct-24-17 08:14AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 24, 2017 Capital Cube
Oct-19-17 08:00AM  Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda GlobeNewswire
Oct-12-17 08:37AM  Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) Zacks
Oct-11-17 08:25AM  Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences Zacks
Oct-05-17 11:32AM  Calithera Biosciences, Inc. Value Analysis (NASDAQ:CALA) : October 5, 2017 Capital Cube
Oct-04-17 08:27AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 4, 2017 Capital Cube
Oct-03-17 08:00AM  Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel GlobeNewswire
Sep-21-17 04:05PM  Calithera Biosciences Appoints Blake Wise to Board of Directors GlobeNewswire
Sep-20-17 08:00AM  Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable GlobeNewswire
Sep-19-17 03:11PM  Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting GlobeNewswire
Sep-12-17 11:31AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : September 12, 2017 Capital Cube
Sep-11-17 07:30PM  5 Ways To Play The Biotech Bull Market Oilprice.com
Sep-08-17 08:50AM  Earnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy? Zacks
Sep-04-17 04:42PM  Here Are 3 Strong Biotech Stocks In 2017 Forbes
Aug-30-17 08:00AM  Calithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference GlobeNewswire
Aug-23-17 08:53AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : August 23, 2017 Capital Cube
Aug-11-17 07:11PM  Edited Transcript of CALA earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents +15.35%
Aug-08-17 11:31PM  Calithera reports 2Q loss Associated Press
04:06PM  Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
10:00AM  Investor Network: Calithera Biosciences, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 07:00AM  Calithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma GlobeNewswire
Aug-04-17 08:23PM  Calithera Biosciences, Inc. Value Analysis (NASDAQ:CALA) : August 5, 2017 Capital Cube
Aug-02-17 07:00AM  Calithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017 GlobeNewswire
Jul-24-17 09:30AM  Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : July 24, 2017 Capital Cube
Jul-20-17 09:02PM  3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? Motley Fool
Jul-15-17 06:06AM  3 Stocks That Turned $1,000 Into at Least $2,017 in 12 Months Motley Fool
Jul-11-17 05:08PM  Five Scorching Hot Stocks Screaming Higher Zacks
Jul-10-17 08:48AM  Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) Zacks
Jun-25-17 02:01PM  5 Best Biotech Stocks of 2017 So Far Motley Fool
Jun-16-17 08:41AM  Why Calithera Biosciences (CALA) Could Be Positioned for a Surge Zacks
Jun-14-17 07:00AM  Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference GlobeNewswire
Jun-13-17 08:46AM  This Biotech Name Could Be Best In Breed For 2017 Benzinga
Jun-08-17 08:00AM  Today's Research Reports on Stocks to Watch: Calithera Biosciences and Cerus Corporation Accesswire -7.67%
Jun-07-17 09:45AM  How Calithera Biosciences Won Big With Its Cancer Treatment 24/7 Wall St. +5.84%
06:45AM  Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma GlobeNewswire
Jun-05-17 06:45AM  CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-22-17 10:45AM  3 Under-the-radar Momentum Plays Investopedia
08:45AM  Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences Accesswire
May-11-17 02:23PM  Edited Transcript of CALA earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-10-17 03:13PM  Here's Why Calithera Biosciences Stock Gained as Much as 16.4% Today Motley Fool +17.26%
06:59AM  Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma Business Wire
May-09-17 05:16PM  Calithera reports 1Q loss Associated Press
04:06PM  Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
10:30AM  Investor Network: Calithera Biosciences, Inc. to Host Earnings Call Accesswire
May-03-17 07:30AM  Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 GlobeNewswire
Apr-20-17 10:33AM  CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting GlobeNewswire
Apr-13-17 09:30AM  Zacks.com featured highlights: Calithera Biosciences, Weibo, Genco Shipping & Trading, Everi Holdings and Willdan Group Zacks
Apr-05-17 09:27AM  Q1 Roundup: Winners and Losers of Biotech Sector Investopedia
09:27AM  Q1 Roundup: Winners and Losers of Biotech Sector
Apr-03-17 10:59AM  Best ETFs & Stocks from Top Sectors of Q1 Zacks
10:59AM  Best ETFs & Stocks from Top Sectors of Q1
Mar-29-17 07:00AM  Calithera Biosciences to Present at the 16th Annual Needham Health Care Conference GlobeNewswire
Mar-28-17 07:00AM  Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study GlobeNewswire
Mar-27-17 04:04PM  Calithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares GlobeNewswire
Mar-23-17 01:04PM  CALITHERA BIOSCIENCES, INC. Financials
Mar-22-17 07:00AM  Calithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock GlobeNewswire
06:12AM  CALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-20-17 04:02PM  Calithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock GlobeNewswire
Mar-17-17 10:41AM  Edited Transcript of CALA earnings conference call or presentation 16-Mar-17 5:30pm GMT Thomson Reuters StreetEvents -9.49%
10:41AM  Edited Transcript of CALA earnings conference call or presentation 16-Mar-17 5:30pm GMT
Mar-16-17 05:30PM  Calithera reports 4Q loss Associated Press
05:30PM  Calithera reports 4Q loss
04:30PM  Calithera Biosciences Inc Earnings Call scheduled for 4:30 pm ET today
04:08PM  CALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
04:06PM  Calithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights GlobeNewswire
07:07AM  Q4 2016 Calithera Biosciences Inc Earnings Release - Time Not Supplied
Mar-14-17 08:30AM  Calithera Biosciences (CALA) Rises: Stock Moves Up 19.3%
06:02AM  Rev's Forum: Don't Underestimate the Power of a Plodding Market
Mar-13-17 04:45PM  CALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers +19.34%
Mar-10-17 07:00AM  Calithera Biosciences to Report Fourth Quarter and Year-End 2016 Financial Results on Thursday, March 16, 2017 GlobeNewswire
Mar-07-17 10:20AM  Biotech Bounce Set to Pick Up Steam at Investopedia
Mar-06-17 07:04AM  Four Companies Breaking Out Right Now With Record Growth -5.65%
Mar-02-17 11:15AM  Shark Bites: Market Taking a Break, but Probably Not for Long
Mar-01-17 07:00AM  Calithera Biosciences to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire +28.89%
Feb-09-17 07:00AM  Calithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February GlobeNewswire
Jan-31-17 01:30PM  Calithera Biosciences Inc (CALA): What You Need To Know at Insider Monkey
11:26AM  Incyte Pays $53M for Calitheras Oncology Drug at Investopedia
09:55AM  Incyte and Calithera Enter into Deal for Oncology Candidate
09:30AM  Biotech Acquisitions on the Rise in 2017: Latest Reports on Calithera Biosciences and Evoke Pharma Accesswire
08:50AM  Is the Options Market Predicting a Spike in Calithera Biosciences (CALA) Stock?
08:45AM  Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%
Jan-30-17 05:28PM  CALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and +46.74%
11:45AM  $53M deal: Incyte acquires rights to experimental cancer therapy at bizjournals.com
10:50AM  Why This Collaboration Is So Important for Calithera
06:45AM  Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor GlobeNewswire
Jan-24-17 10:38AM  How Bristol-Myers Squibbs Oncology Drug Performed in 4Q16 +7.95%
06:28AM  Calithera Biosciences upgraded by Citigroup
Jan-06-17 09:16AM  Can The Uptrend Continue for Calithera Biosciences (CALA)? +12.66%
Dec-27-16 03:28PM  Biotech Stocks to Watch After Senate Drug Report
Dec-22-16 10:22AM  Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerSep 28Sale15.5038,000589,0003,546,873Sep 28 04:10 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerSep 27Sale15.59186,0002,899,7403,584,873Sep 28 04:10 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerSep 26Sale15.68352,0005,519,3603,770,873Sep 28 04:10 PM
Wong StephanieVP, FINANCE AND SECRETARYJul 17Sale18.413,55265,38510,550Jul 19 04:06 PM
Orford KeithSR. VP, CLINICAL DEVELOPMENTJul 17Sale18.312,12038,8236,879Jul 19 04:05 PM
Hecht CurtisSVP, BUS. & CORP. DEVELOPMENTJul 06Sale18.0070012,60015,940Jul 07 04:07 PM
Hecht CurtisSVP, BUS. & CORP. DEVELOPMENTMay 19Sale16.0065010,40014,910May 23 04:05 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerMar 22Buy10.25487,8044,999,9914,122,873Mar 24 10:00 AM
Hecht CurtisSVP, BUS. & CORP. DEVELOPMENTMar 13Sale14.006008,40015,560Mar 15 04:05 PM
Hecht CurtisSee RemarksMar 02Sale12.005506,60016,160Mar 06 04:05 PM
Molineaux ChristopherSR. VP, DEVELOPMENTDec 19Option Exercise1.7410,16717,73912,044Dec 20 09:00 AM
Molineaux SusanPRESIDENT AND CEODec 19Option Exercise2.1621,93347,30923,810Dec 20 09:00 AM